Bayer partners with Kumquat Biosciences to advance a promising Kras G12D cancer treatment, aiming to address critical unmet ...

Under the global exclusive license deal, Kumquat will be responsible for the Phase 1a study of its inhibitor and Bayer will ...

BERLIN (Reuters) -German pharmaceutical group Bayer announced on Tuesday a deal worth up to $1.3 billion with Kumquat ...

The deal – which has a total value of up to $1.3 billion including an unspecified upfront payment – gives Bayer exclusive ...

For $1.3 billion in aggregate—including upfront and milestone payments—Bayer will get exclusive global access to Kumquat ...

Bayer Leverkusen have announced the signing of Ernest Poku (21) from AZ Alkmaar for a reported €12m including bonuses. The ...

Another Massachusetts biotech has reached the end of the road. | Another Massachusetts biotech has reached the end of the ...

Investor concerns that Bayer's earnings were inflated by soccer player transfer fees rather than supported by its core ...

The German pharma will license a KRAS G12D inhibitor from Kumquat Biosciences. Elsewhere, a Biohaven OCD drug missed its ...

An announcement from Board of Education President Steven Blair on Friday said Mike Dominguez resigned July 31 to "pursue ...